These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28412912)

  • 1. The Socioeconomic Effects of Uncontrolled Hypertension.
    Athanasakis K
    Curr Vasc Pharmacol; 2017; 16(1):5-9. PubMed ID: 28412912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of health outcome and associated costs in cardiovascular disease.
    Jönsson B
    Eur Heart J; 1996 Mar; 17 Suppl A():2-7. PubMed ID: 8737194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria and clinical outcomes in hypertensive patients.
    Maione A; Annemans L; Strippoli G
    Am J Hypertens; 2009 Nov; 22(11):1137-47. PubMed ID: 19730418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension, a health economics perspective.
    Alcocer L; Cueto L
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):147-55. PubMed ID: 19124418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors.
    Frieden TR; Jaffe MG
    J Clin Hypertens (Greenwich); 2018 Feb; 20(2):208-211. PubMed ID: 29370471
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic approach to the control of hypertension. Its impact on health policy.
    Arroyo P; Herrera J; Fernandez V
    Clin Exp Hypertens; 1995 Oct; 17(7):1121-6. PubMed ID: 8556009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Pharmacists' Work in a Physician-Pharmacist Collaborative Model for the Management of Hypertension.
    Isetts BJ; Buffington DE; Carter BL; Smith M; Polgreen LA; James PA
    Pharmacotherapy; 2016 Apr; 36(4):374-84. PubMed ID: 26893135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of blood pressure-related disease: a neglected priority for global health.
    Perkovic V; Huxley R; Wu Y; Prabhakaran D; MacMahon S
    Hypertension; 2007 Dec; 50(6):991-7. PubMed ID: 17954719
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of hypertension treatment.
    Ménard J
    Clin Exp Hypertens; 1996; 18(3-4):399-413. PubMed ID: 8743030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of treating hypertension in the elderly.
    Roberts RL; Small RE
    Curr Hypertens Rep; 2002 Dec; 4(6):420-3. PubMed ID: 12419169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct cost of systemic arterial hypertension and its complications in the circulatory system from the perspective of the Brazilian public health system in 2019.
    Curado DDSP; Gomes DF; Silva TBC; Almeida PHRF; Tavares NUL; Areda CA; da Silva EN
    PLoS One; 2021; 16(6):e0253063. PubMed ID: 34111216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Costs Attributable to Hypertension: Canadian Population-Based Cohort Study.
    Weaver CG; Clement FM; Campbell NR; James MT; Klarenbach SW; Hemmelgarn BR; Tonelli M; McBrien KA;
    Hypertension; 2015 Sep; 66(3):502-8. PubMed ID: 26169049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.